Malignant neoplasm of breast of unspecified site, female
- C50.91 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
- The 2024 edition of ICD-10-CM C50.91 became effective on October 1, 2023.
- This is the American ICD-10-CM version of C50.91 – other international versions of ICD-10 C50.91 may differ.
The following code(s) above C50.91 contain annotation back-references
that may be applicable to C50.91:
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- 2024 (effective 10/1/2023): No change
Diagnosis Index entries containing back-references to C50.91:
- Adenocarcinoma – see also Neoplasm, malignant, by site
- duct
- infiltrating
- unspecified site (female) C50.91-
- infiltrating
- infiltrating duct
- unspecified site (female) C50.91-
- inflammatory
- unspecified site (female) C50.91-
- intraductal
- noninfiltrating
- papillary
- with invasion
- unspecified site (female) C50.91-
- with invasion
- papillary
- papillary
- with invasion
- unspecified site (female) C50.91-
- with invasion
- noninfiltrating
- lobular
- unspecified site (female) C50.91-
- papillary
- intraductal (noninfiltrating)
- with invasion
- unspecified site (female) C50.91-
- with invasion
- intraductal (noninfiltrating)
- duct
- Cancer – see also Neoplasm, by site, malignant
- breast C50.91- – see also Neoplasm, breast, malignant
- Carcinoma (malignant) – see also Neoplasm, by site, malignant
- duct (cell)
- infiltrating
- with lobular carcinoma (in situ)
- unspecified site (female) C50.91-
- specified site – see Neoplasm, malignant, by site
- unspecified site (female) C50.91-
- with lobular carcinoma (in situ)
- infiltrating
- ductal
- with lobular
- unspecified site (female) C50.91-
- with lobular
- ductular, infiltrating
- unspecified site (female) C50.91-
- infiltrating
- duct
- with lobular
- unspecified site (female) C50.91-
- unspecified site (female) C50.91-
- with lobular
- ductular
- unspecified site (female) C50.91-
- lobular
- unspecified site (female) C50.91-
- duct
- inflammatory
- unspecified site (female) C50.91-
- intraductal (noninfiltrating)
- papillary
- with invasion
- unspecified site (female) C50.91-
- with invasion
- papillary
- lipid-rich (female) C50.91-
- lobular (infiltrating)
- with intraductal
- unspecified site (female) C50.91-
- unspecified site (female) C50.91-
- with intraductal
- medullary
- with
- lymphoid stroma
- unspecified site (female) C50.91-
- lymphoid stroma
- with
- papillary
- intraductal (noninfiltrating)
- with invasion
- unspecified site (female) C50.91-
- with invasion
- intraductal (noninfiltrating)
- duct (cell)
- Carcinoma-in-situ – see also Neoplasm, in situ, by site
- lobular
- with
- infiltrating duct
- breast (female) C50.91-
- unspecified site (female) C50.91-
- infiltrating duct
- with
- lobular
- Disease, diseased – see also Syndrome
- breastN64.9 – see also Disorder, breast
- Paget’s
- female, unspecified side C50.91-
- Paget’s
- breastN64.9 – see also Disorder, breast